Drug sensitivity experiments revealed that EMC2 overexpression sensitizes breast cancer cells to PDK1 or AKT inhibition both in vitro and in vivo, whereas EMC2 silencing has the opposite effect. Here, PDK1 is linked to breast carcinoma.